B cell-based therapies in CNS autoimmunity

differentiating CD19 and CD20 as therapeutic targets

Thomas G. Forsthuber, Daniel M. Cimbora, John Nolan Ratchford, Eliezer Katz, Olaf Stüve

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Increasing recognition of the role of B cells in the adaptive immune response makes B cells an important therapeutic target in autoimmunity. Numerous current and developmental immunotherapies target B cells for elimination through recognition of cell-surface proteins expressed specifically on B cells, in particular CD19 and CD20. Similarities and differences in the function and expression of these two molecules predict some shared, and some distinct, pharmacological effects of agents targeting CD19 versus CD20, potentially leading to differences in the clinical safety and efficacy of such agents. Here, we review current knowledge of CD19 and CD20 function and biology, survey current and developmental therapies that target these molecules, and discuss potential differences in elimination of B cells by drugs that target CD19 versus CD20, with particular focus on the central nervous system autoimmune diseases multiple sclerosis and neuromyelitis optica. The principles and mechanisms herein discussed might also be relevant to a variety of other nervous system autoimmune disorders, including NMDA (N-methyl-D-aspartate) receptor encephalitis, transverse myelitis and myasthenia gravis.

Original languageEnglish (US)
JournalTherapeutic Advances in Neurological Disorders
Volume11
DOIs
StatePublished - Jan 1 2018

Fingerprint

Cell- and Tissue-Based Therapy
Autoimmunity
B-Lymphocytes
Autoimmune Diseases of the Nervous System
Transverse Myelitis
Neuromyelitis Optica
Therapeutics
Central Nervous System Diseases
Myasthenia Gravis
Adaptive Immunity
Encephalitis
N-Methyl-D-Aspartate Receptors
Immunotherapy
Multiple Sclerosis
Membrane Proteins
Pharmacology
Safety
Pharmaceutical Preparations

Keywords

  • autoimmunity
  • B cells
  • CD19
  • CD20
  • experimental autoimmune encephalomyelitis
  • multiple sclerosis
  • neuromyelitis optica
  • neuromyelitis optica spectrum disorder
  • pharmacology
  • plasma cells
  • plasmablasts

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Cite this

B cell-based therapies in CNS autoimmunity : differentiating CD19 and CD20 as therapeutic targets. / Forsthuber, Thomas G.; Cimbora, Daniel M.; Ratchford, John Nolan; Katz, Eliezer; Stüve, Olaf.

In: Therapeutic Advances in Neurological Disorders, Vol. 11, 01.01.2018.

Research output: Contribution to journalReview article

Forsthuber, Thomas G. ; Cimbora, Daniel M. ; Ratchford, John Nolan ; Katz, Eliezer ; Stüve, Olaf. / B cell-based therapies in CNS autoimmunity : differentiating CD19 and CD20 as therapeutic targets. In: Therapeutic Advances in Neurological Disorders. 2018 ; Vol. 11.
@article{cd696894a2fa422f806821cf1817d62f,
title = "B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets",
abstract = "Increasing recognition of the role of B cells in the adaptive immune response makes B cells an important therapeutic target in autoimmunity. Numerous current and developmental immunotherapies target B cells for elimination through recognition of cell-surface proteins expressed specifically on B cells, in particular CD19 and CD20. Similarities and differences in the function and expression of these two molecules predict some shared, and some distinct, pharmacological effects of agents targeting CD19 versus CD20, potentially leading to differences in the clinical safety and efficacy of such agents. Here, we review current knowledge of CD19 and CD20 function and biology, survey current and developmental therapies that target these molecules, and discuss potential differences in elimination of B cells by drugs that target CD19 versus CD20, with particular focus on the central nervous system autoimmune diseases multiple sclerosis and neuromyelitis optica. The principles and mechanisms herein discussed might also be relevant to a variety of other nervous system autoimmune disorders, including NMDA (N-methyl-D-aspartate) receptor encephalitis, transverse myelitis and myasthenia gravis.",
keywords = "autoimmunity, B cells, CD19, CD20, experimental autoimmune encephalomyelitis, multiple sclerosis, neuromyelitis optica, neuromyelitis optica spectrum disorder, pharmacology, plasma cells, plasmablasts",
author = "Forsthuber, {Thomas G.} and Cimbora, {Daniel M.} and Ratchford, {John Nolan} and Eliezer Katz and Olaf St{\"u}ve",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1756286418761697",
language = "English (US)",
volume = "11",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - B cell-based therapies in CNS autoimmunity

T2 - differentiating CD19 and CD20 as therapeutic targets

AU - Forsthuber, Thomas G.

AU - Cimbora, Daniel M.

AU - Ratchford, John Nolan

AU - Katz, Eliezer

AU - Stüve, Olaf

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Increasing recognition of the role of B cells in the adaptive immune response makes B cells an important therapeutic target in autoimmunity. Numerous current and developmental immunotherapies target B cells for elimination through recognition of cell-surface proteins expressed specifically on B cells, in particular CD19 and CD20. Similarities and differences in the function and expression of these two molecules predict some shared, and some distinct, pharmacological effects of agents targeting CD19 versus CD20, potentially leading to differences in the clinical safety and efficacy of such agents. Here, we review current knowledge of CD19 and CD20 function and biology, survey current and developmental therapies that target these molecules, and discuss potential differences in elimination of B cells by drugs that target CD19 versus CD20, with particular focus on the central nervous system autoimmune diseases multiple sclerosis and neuromyelitis optica. The principles and mechanisms herein discussed might also be relevant to a variety of other nervous system autoimmune disorders, including NMDA (N-methyl-D-aspartate) receptor encephalitis, transverse myelitis and myasthenia gravis.

AB - Increasing recognition of the role of B cells in the adaptive immune response makes B cells an important therapeutic target in autoimmunity. Numerous current and developmental immunotherapies target B cells for elimination through recognition of cell-surface proteins expressed specifically on B cells, in particular CD19 and CD20. Similarities and differences in the function and expression of these two molecules predict some shared, and some distinct, pharmacological effects of agents targeting CD19 versus CD20, potentially leading to differences in the clinical safety and efficacy of such agents. Here, we review current knowledge of CD19 and CD20 function and biology, survey current and developmental therapies that target these molecules, and discuss potential differences in elimination of B cells by drugs that target CD19 versus CD20, with particular focus on the central nervous system autoimmune diseases multiple sclerosis and neuromyelitis optica. The principles and mechanisms herein discussed might also be relevant to a variety of other nervous system autoimmune disorders, including NMDA (N-methyl-D-aspartate) receptor encephalitis, transverse myelitis and myasthenia gravis.

KW - autoimmunity

KW - B cells

KW - CD19

KW - CD20

KW - experimental autoimmune encephalomyelitis

KW - multiple sclerosis

KW - neuromyelitis optica

KW - neuromyelitis optica spectrum disorder

KW - pharmacology

KW - plasma cells

KW - plasmablasts

UR - http://www.scopus.com/inward/record.url?scp=85054569858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054569858&partnerID=8YFLogxK

U2 - 10.1177/1756286418761697

DO - 10.1177/1756286418761697

M3 - Review article

VL - 11

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

ER -